Vita 34 AG Logo

Vita 34 AG

ISIN

DE000A0BL849

Ticker

V3V

Sector

Health Care

Sub-Industry

Health Care Services

Country

Germany

Year Founded

1997

About Vita 34 AG

Company Description

Vita 34 was founded in Leipzig in 1997 and is today one of the leading cell banks in Europe. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since then been a complete provider of cryopreservation services for the collection, processing and storage of stem cells from umbilical cord blood and umbilical cord tissue.
Based on the expansion of the business model in 2019, Vita 34 intends to also offer the storage of immune cells from peripheral blood as well as of stem cells from endogenous fat in the future. Endogenous cells are a valuable source of medical cell therapy and are kept alive at temperatures as low as minus 200 degrees Celsius to be used as part of a treatment when needed.

Headcount

120

Served Area

Europe

Headquarters

Deutscher Platz 5a
4103, Leipzig
Germany

Filings & Publications

  • Consolidated Report 2021 - Q1 English 🇬🇧
  • Consolidated Report 2021 - Q1 German 🇩🇪
  • Consolidated Report 2021 - Q2 German 🇩🇪
  • Consolidated Report 2021 - Q2 English 🇬🇧
  • Consolidated Report 2021 - Q3 German 🇩🇪
  • Consolidated Report 2021 - Q3 English 🇬🇧
  • Consolidated Report 2021 - Q4 English 🇬🇧
  • Consolidated Report 2020 - Q1 German 🇩🇪
  • Consolidated Report 2020 - Q1 English 🇬🇧
  • Consolidated Report 2020 - Q2 German 🇩🇪
  • Consolidated Report 2020 - Q2 English 🇬🇧
  • Consolidated Report 2020 - Q3 German 🇩🇪
  • Consolidated Report 2020 - Q3 English 🇬🇧
  • Consolidated Report 2020 - Q4 English 🇬🇧
  • Consolidated Report 2019 - Q1 German 🇩🇪
  • Consolidated Report 2019 - Q1 English 🇬🇧
  • Consolidated Report 2019 - Q2 German 🇩🇪
  • Consolidated Report 2019 - Q2 English 🇬🇧
  • Consolidated Report 2019 - Q3 English 🇬🇧
  • Consolidated Report 2019 - Q3 German 🇩🇪
  • Consolidated Report 2019 - Q4 German 🇩🇪
  • Consolidated Report 2019 - Q4 English 🇬🇧
  • Consolidated Report 2018 - Q3 German 🇩🇪
  • Consolidated Report 2018 - Q3 English 🇬🇧
  • Consolidated Report 2018 - Q4 German 🇩🇪
  • Consolidated Report 2018 - Q4 English 🇬🇧
  • Consolidated Report 2022 - Q1 German 🇩🇪
  • Consolidated Report 2022 - Q1 English 🇬🇧
  • Consolidated Report 2022 - Q2 English 🇬🇧
  • Company Presentation 2022 - Q2 German 🇩🇪
  • Consolidated Report 2022 - Q3 English 🇬🇧
  • Company Presentation 2022 - Q4 German 🇩🇪

Insider Trades

Date Trading entity / Person Association Trade type Volume
11.12.2023 AOC Health GmbH Close relation Other EUR 6,572,680.40
11.12.2023 Baran, Jakub Julian Other Buy EUR 99,998.80
28.09.2022 Dr. Granderath, Rat und Vermögen GmbH Close relation Buy EUR 21,557.28
02.06.2022 Dr. Granderath, Rat und Vermögen GmbH Close relation Buy EUR 33,000.00
02.06.2022 Schweppe, Thomas Supervisory board Other EUR 0.00
18.11.2021 Lorenzen, Hans-Jochen Supervisory board Sell EUR 180,625.00
10.11.2021 Project Mill Gesellschaft für interdisziplinären Know-how-Transfer GmbH Close relation Other EUR 36,146.25
09.11.2021 Zeitfracht GmbH & Co. KGaA Close relation Sell EUR 35,525.00
09.11.2021 von Blücher, Dietmar Board Buy EUR 28,820.00
09.11.2021 von Blücher, Dietmar Board Buy EUR 14,400.00

Capital Markets Information

ISIN

DE000A0BL849

LEI

529900OEWA4GSZEZ4P40

Designated Sponsor

Hauck Aufhäuser Lampe Privatbank AG

Listed Stock Exchange

Frankfurt Stock Exchange

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.